Evidence map›Paper›PMID 42468515›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Single-Cell Dissection of Therapy-Induced Remodeling Uncovers a Fibroblast-Driven Immunosuppressive Niche and Targetable Vulnerabilities in Lethal Prostate Cancer.

Yang Chen, Dandan Dong, Jinling Liao, Naikai Liao, Mengqi Liu, Qin Zhang, Siting Chen, Qi Liu, Ying Lu, Tianyu Li and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Yang ChenDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Dandan DongKey Laboratory of Metabolism and Molecular Medicine of the Ministry of Education & Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, and Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China.
Jinling LiaoCenter For Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, University Engineering Research Center of Digital Medicine and Healthcare, School of Life Science, Guangxi Medical University, Nanning, Guangxi, China.
Naikai LiaoDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Mengqi LiuKey Laboratory of Metabolism and Molecular Medicine of the Ministry of Education & Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, and Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China.
Qin ZhangState Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, Jiangsu, China.
Siting ChenKey Laboratory of Metabolism and Molecular Medicine of the Ministry of Education & Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, and Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China.
Qi LiuKey Laboratory of Metabolism and Molecular Medicine of the Ministry of Education & Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, and Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China.
Ying LuKey Laboratory of Metabolism and Molecular Medicine of the Ministry of Education & Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, and Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China.
Tianyu LiDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Chunlin ZouKey Laboratory of Longevity and Aging-Related Disease of Chinese Ministry of Education, Center for Translational Medicine, School of Basic Medical Sciences, Guangxi Medical University, Nanning, Guangxi, China.
Qiong SongKey Laboratory of Longevity and Aging-Related Disease of Chinese Ministry of Education, Center for Translational Medicine, School of Basic Medical Sciences, Guangxi Medical University, Nanning, Guangxi, China.
Qiuyan WangCenter For Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, University Engineering Research Center of Digital Medicine and Healthcare, School of Life Science, Guangxi Medical University, Nanning, Guangxi, China.
Jian LiangDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Qiji XieDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Chengyang LiDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Mengyun WangCancer Institute, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College of Fudan University, Shanghai, China.
Jiwen ChengDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Zengnan MoDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Gong-Hong WeiKey Laboratory of Metabolism and Molecular Medicine of the Ministry of Education & Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, and Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0001-6546-9334

Funding

First-class discipline innovation-driven talent program of Guangxi Medical University DC2500001200First-class discipline innovation-driven talent program of Guangxi Medical University DC2500001220Guangxi key Laboratory for Genomic and Personalized Medicine 22-35-17Guangxi Key Research and Development Project uikeAB21196022Guangxi Natural Science Foundation 2022JJB140197Guangxi Natural Science Foundation 2024JJA141067Guangxi Natural Science Foundation 2024JJB140509Guangxi Science and Technology Major Project GuikeAA22096030Guangxi Science and Technology Major Project GuikeAA22096032Guangxi Science and Technology Program under Grant No.LT2600640048Guangxi Young Elite Scientist Sponsorship Program GXYESS2026031Major Project of Guangxi Innovation Driven AA18118016National Natural Science Foundation of China 82060145National Natural Science Foundation of China 82073082National Natural Science Foundation of China 82160482National Natural Science Foundation of China 82270806National Natural Science Foundation of China 82311530050National Natural Science Foundation of China 82460596Shanghai International Collaborative Project 23410713300
6 · The paper itself

Abstract

Therapy resistance in prostate cancer arises from coordinated remodeling of malignant and stromal compartments, yet the mechanisms orchestrating this ecosystem adaptation remain elusive. Here, single-cell RNA sequencing of longitudinal biopsies obtained before and after androgen-deprivation therapy (ADT) delineated a therapy-induced stromal lineage bifurcation toward APOD

Indexed as

androgen deprivationcomplementDPT+ fibroblastneuroendocrine differentiationNRXN1T‐cell exhaustionTSPAN1

Identifiers

PMID42468515
PMCPMC13379274

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.